CMV
FLORENCE | ITALY
FROM PREGNANCY TO INFANCY: LET’S FACE IT
cmvcongress.eu
21-22 FEBRUARY
2019
2
CONGRESS PRESIDENTS:
Yves Ville, FranceEfraim Bilavsky, Israel
FACULTY:
Jacob Amir, IsraelDaniel Blázquez-Gamero, SpainLinda de Vries, the Netherlands
Elisa Fabbri, ItalyIna Foulon, Belgium
Chrissie Jones, United KingdomAsma Khalil, United KingdomDavid Kimberlin, United States
Tiziana Lazzarotto, ItalyMarianne Leruez-Ville, France
Daniele Lilleri, ItalyShlomo Lipitz, IsraelAlbert Park, USA
Olivier Picone, FranceMark Schleiss, USA
Giuliana Simonazzi, ItalyNatasha Teissier, France
Ann Vossen, the Netherlands
3
FIRST DAYTHURSDAY 21 FEBRUARY 2019
09.00 - 09.10 WELCOME FROM CONGRESS PRESIDENTS
09.10 - 10.00 DEBATE Moderators: Shlomo Lipitz, Israel; Giuliana Simonazzi, Italy
Prenatal screening YES/NO Yves Ville/Asma Khalil
10.00 - 11.30 PREVENTION AND TREATMENT OF PRIMARY INFECTION DURING PREGNANCY Moderators: Tiziana Lazzarotto, Italy; Yves Ville, France
10.00 - 10.20 Attitude/educational and hygienic measures Olivier Picone, France
10.20 - 10.40 Antiviral treatment Marianne Leruez-Ville, France
10.40 - 11.00 Passive and active vaccinations during pregnancy Daniele Lilleri, Italy
11.00 - 11.10 Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects Rituparna Das, United States
11.10 - 11.20 Development of a digital antenatal educational intervention to reduce the risk of acquisition of CMV in pregnancy: working in partnership with pregnant women and families affected by CMV Chrissie Jones, United Kingdom
11.20 - 11.30 Panel Discussion
4
11.30 - 12.00 COFFEE BREAK
12.00 - 13.30 TREATMENT OF CHILDREN WITH CCMV Moderators: Jacob Amir, Israel; Daniel Blázquez-Gamero, Spain
12.00 - 12.20 Deciding to treat symptomatic congenital CMV: extent of involvement and use of biomarkers David Kimberlin, United States
12.20 - 12.40 Who is afraid of prolonged Valganciclovir treatment? Ann Vossen, The Netherlands
12.40 - 13.00 Treatment of Congenital CMV Infection: new populations, new regimens, and new drugs? David Kimberlin, United States
13.00 - 13.10 Targeting peptidyl arginine deiminase type 2 (PAD2) is a promising therapeutic option against congenital HCMV infections Marco De Andrea, Italy
13.10 - 13.20 Baseline Brain Magnetic Resonance Imaging (MRI) for Children with Congenital Cytomegalovirus (cCMV) - a retrospective analysis Hermione Lyall, United Kingdom
13.20 - 13.30 Panel Discussion
13.30 - 14.30 LUNCH BREAK
14.30 - 15.45 DIAGNOSIS OF FETAL DISEASE DURING PREGNANCY Moderators: Mark Schleiss, United States; Daniele Lilleri, Italy
14.30 - 14.55 How to diagnose a primary infection Tiziana Lazzarotto, Italy
14.55 - 15.15 How to diagnose a non primary infection Marianne Leruez-Ville, France
5
15.15 - 15.40 The value of ultrasound screening for CMV infection Giuliana Simonazzi, Italy
15.40 - 15.50 Role of ultrasound examination in predicting newborn sequelae in pregnancies complicated by Cytomegalovirus infection: a single center co-hort Agnese Comelli, Italy
15.50 - 16.00 CMV-DNA evaluation in maternal urine and plasma: the role on the vertical transmission Giuseppina Esposito, Italy
16.00 - 16.15 Panel Discussion
16.15 - 16.45 COFFEE BREAK
16.45 - 17.30 DEBATE ON PRO VS CONS ON NON-PRIMARY INFECTION DIAGNOSIS IN PREGNANCY Moderator: Chrissie Jones, United Kingdom Speakers: Marianne Leruez-Ville, France and Tiziana Lazzarotto, Italy
6
09.00 - 10.45 HEARING LOSS AND VESTIBULAR DISORDERS IN CCMV Moderators: Albert Park, United States; Efraim Bilavsky, Israel
09.00 - 09.25 Hearing rehabilitation in children with cCMV (including unilateral hearing loss) Ina Foulon, Belgium
09.25 - 09.50 Treatment of isolated hearing loss Chrissie Jones, United Kingdom
09.50 - 10.15 Vestibular disorders in children with congenital Cytomegalovirus Infection Natacha Teissier, France
10.15 - 10.25 Vestibular function in children with congenital cytomegalovirus infection: results of 2.5 years of follow-up Cleo Dhondt, Belgium
10.25 - 10.45 Panel Discussion
10.45 - 11.20 COFFEE BREAK
11.20 - 12.00 ACCEPTED ORAL LECTURES Moderators: Linda De Vries, The Netherlands; Ina Foulon, Belgium
11.20 - 11.30 Evaluation of a new molecular assay for newborn cytomegalovirus testing using oral dried swab samples Angela Chiereghin, Italy
11.30 - 11.40 Monitoring CMV infection in pregnancy in the province of Trento 2007-2016 Silvano Piffer, Italy
SECOND DAYFRIDAY 22 FEBRUARY 2019
7
11.40 - 11.50 Targeted neonatal screening for congenital CMV - a single center experience Joseph Pardo, Israel
11.50 - 12.00 Neonatal neuroimaging in symptomatic congenital CMV (cCMV) and its orrelation with outcome: emphasis on white matter disease Ana Alarcon, Spain
12.00 - 13.30 PROGNOSTIC EVALUATION OF FETAL INFECTION Moderators: Shlomo Lipitz, Israel; Daniele Lilleri, Italy
12.00 - 12.20 The right combination of ultrasound and MRI Yves Ville, France
12.20 - 12.40 Fetal blood prognostic factors Elisa Fabbri, Italy
12.40 - 13.00 The impact of cCMV on the brain of preterm infants Linda de vries, The Netherlands
13.00 - 13.10 Fetal neuroimaging as a prognostic tool for congenital CMV infection Jacob Amir, Israel
13.10 – 13.20 The role of MRI in fetal CMV infection Shlomo Lipitz, Israel
13.20 – 13.30 Panel Discussion
13.30 - 14.30 LUNCH BREAK
14.30 - 16.00 ACCEPTED ORAL LECTURES Moderators: David Kimberlin, United Sates; Ann Vossen, the Nether-lands
14.30 - 14.40 Congenital cytomegalovirus-associated hearing loss: can brain imaging predict hearing outcome? Ingeborg Dhooge, Belgium
8
14.40 - 14.50 Performance and outcome of a multi-hospital programmatic congenital cytomegalovirus (cCMV) universal newborn screening program John DeVincenzo, United States
14.50 - 15.00 Prevalence and clinical manifestations of congenital cytomegalovirus infection in a screening program in Madrid (PICCSA Study) Daniel Blázquez-Gamero, Spain
15.00 - 15.10 Another Look at Dried Blood Spot (DBS) PCR for Diagnosis of Congenital CMV (cCMV) Infection: Results from a Minnesota Universal Newborn Screening Study Mark Schleiss, United States
15.10 - 15.20 Universal congenital CMV infection (cCMV) screening: a three-years single center experience Simona Fiorentini, Italy
15.20 - 15.30 Treatment of children born with congenital cytomegalovirus infection beyond the neonatal period Lev Dorfman, Israel
15.30 - 15.40 Prospective multi-center comparison of urine culture with PCR from DBS using two different extraction and PCR methods in neonates Elizaveta Padalko, Belgium
15.40 - 15.50 Yield of urine for CMV screening test for asymptomatic micro-cephalic infants Haroon Usman, Ireland
9
15.50 - 16.40 DEBATE Moderators: David Kimberlin, United Sates; Ann Vossen, the Netherlands
Is it the time for universal screening for cCMV? YES Efraim Bilavky, Israel NO Ann Vossen, the Netherlands
16.40 CLOSING REMARKS Yves Ville, Efraim Bilavsky
10
POSTER LIST
PLEASE DISPLAY YOUR POSTER IN THE POSTER AREA ACCORDING TO YOUR NUMBER LISTED BELOW
1 SEVERE CONGENITAL CYTOMEGALOVIRUS INFECTION FOLLOWING EARLY RECURRENT INFECTION DURING PREGNANCY B. Resch; M. Grillitsch; M. Häusler; C. Koidl; E. Karpf; B. Urlesberger
2 SEVERE FORM OF THE HYDROTHORAX ASSOCIATED WITH RIGHT DIVIDED ATRIUM AND CYTOMEGALOVIRUS INFECTION - PRENATAL DIAGNOSIS AND OUTCOMES R.Bejiqi; R. Retkoceri; A. Maloku; N. Zeka; A. Vuçiterna; A. Mustafa; A. Gerguri; H. Bejiqi 2; R. Bejiqi
3 DESIGN OF AN ENLITE(TM) PCR ASSAY FOR THE DETECTION OF CONGENITAL CYTOMEGALOVIRUS I. Alm-Ndiaye; O. Leppänen; M. Mäkinen; M. Lehmusvaara; A. Ylikoski
4 SECONDARY HEMOPHAGOCYTIC SYNDROME TRIGGERED BY CONGENITAL CYTOMEGALOVIRUS INFECTION E.N. Balashova
5 VESTIBULAR FUNCTION AND MOTOR PERFORMANCE IN INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION: A PRELIMINARY STUDY L. Maes; A. De Kegel; H. Van Waelvelde; E. De Leenheer; H. Van Hoecke; J. Goderis; I. Dhooge
6 PREVENTING CMV INFECTION THROUGH INFORMATION, EDUCATION AND COLLABORATION G. Johnson
7 PULMONARY HYPERTENSION AS A RARE COMPLICATION OF CONGENITAL CYTOMEGALOVIRUS L. Alkoby-Meshulam; J. Amir; D. Lubin; G. Kalinger; G. Gutsman; S. Zangen; E. Bilavsky
11
8 DOES T-CELL MEDIATED IMMUNE RESPONSE TO CYTOMEGALOVIRUS INFECTION PLAY A ROLE IN PREVENTING INTRAUTERINE TRANSMISSION? M. Soriano-Ramos; S. Domínguez-Rodríguez; D. Navarro; E. Albert; M. De La Calle; M. Cabanes; F. Baquero-Artigao; P. Rodríguez Molino; A. García Burguillo; A. Goncé; D. García; E. Gómez; I. Cuadrado; M. C. Viñuela Benéitez; M. Muñ
9 FETAL LIVER VOLUME ASSESSMENT USING MAGNETIC RESONANCE IMAGING IN FETUSES WITH CMV INFECTION A. Hawkins-Villarreal; A. Moreno-Espinosa; N. Hahner; E. Eixarch; A. Nadal; A. Goncé
10 EVIDENCE OF RESISTANCE IN NEONATAL LONG-TERM VALGANCICLOVIR THERAPY F. Garofoli; M. Angelini; C. Achille; M. Zavattoni; L. Bollani; G. Lombardi
11 CMV INFECTION REACTIVATION IN A TWIN PREGNANCY P. Prats; S. Coll; A. Ponce; C. Fortuny; B. Serra
12 SUCCESSFUL TREATMENT OF INTRAUTERINE CYTOMEGALOVIRUS INFECTION OF THE FETUS AND NEWBORN A. Mikhailov ; A. Romanovsky; T. Kashtanova; I. Kyanksep; N. Rogozina; A.Grineva; I. Bazarov
13 DETECTION AND QUANTIFICATION OF CMV IN AMNIOTIC FLUID, URINE AND SALIVA SWAB A. Derome; P. Marechal; C. Kappler; F. Gelas
14 LONG-TERM HEARING AND NEURODEVELOPMENTAL OUTCOMES AMONG CHILDREN WITH SYMPTOMATIC CONGENITAL CMV DISEASE WITH AND WITHOUT GANCICLOVIR THERAPY T.M. Lanzieri; A.C. Caviness; J. Leung; W. Chung; J.L. Baumgardner; R.G. Voigt; P. Blum; S.R. Bialek; G. Demmler-Harrison
15 WHAT DOES THE HALO SIGN MEAN IN FETAL CMV INFECTION? EVALUATION OF SONOGRAPHIC AND HISTOLOGICAL FINDINGS IN 13 CASES A. Goncé; A. Hawkins-Villarreal; E. Eixarch; A. Nadal; S. Planas; F. Figueras 16 FLUCTUATION IN VIRAL LOAD AFTER TREATMENT FOR CONGENITAL CYTOMEGALOVIRUS: A CASE REPORT A. Afjeh; P.Alizadeh
12
17 CONGENITAL CYTOMEGALOVIRUS INFECTION - DIFFERENT MANIFESTATION AND CONSEQUENCES IN TWO CASES S. Prgomet; T. Bošnjak; I. Antončič Furlan 3; G. Tešovič 18 MATERNAL FETAL INFECTIONS AND LONG TERM NEURODEVELOPMENTAL OUTCOMES IN CHILDREN INFECTED AND UNINFECTED AT BIRTH C. Auriti; S. Bucci; M.P. Ronchetti; A. Santisi; F. Piersigilli; S. Lozzi; I. Bersani; F. Campi; S. Gentile; A. Dotta
19 A NEW MRI SEVERITY SCORE TO PREDICT LONG-TERM ADVERSE NEUROLOGIC OUTCOMES IN CHILDREN WITH CONGENITAL CYTOMEGALOVIRUS INFECTION G. Lucignani; M.C. Rossi Espagne; A. Napolitano; L. Figà Talamanca; F.I.Calò Carducci; C.Auriti; D.Longo
20 SYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTION IN NEWBORNS: BIRTH PREVALENCE AND RISK FACTORS A. Vaniarkina; A. Petrova; L. Rychkova
21 CONGENITAL CYTOMEGALOVIRUS INFECTION IN HIV-EXPOSED UNINFECTED NEWBORNS A. Petrova ; A.Vaniarkina
22 NEUROCOGNITIVE OUTCOME IN SYMPTOMATIC AND ASYMPTOMATIC NEWBORNS WITH CONGENITAL CMV TREATED WITH VALGANCICLOVIR A. Turriziani Colonna; D. Pata; V. Faccia; E. Masiello; G. Salerno; D. Buonsenso; P. Valentini
23 THE IMPORTANCE OF THE POORER-HEARING EAR IN CMV AND ISOLATED HEARING LOSS A. Park; V. Torrecillas; C. Allen; T. Greene; G. Demmler-Harrison
24 CMV CONGENITAL INFECTION: RETROSPECTIVE ANALYSIS OF MATERNAL SEROLOGIES DURING PREGNANCY C. Perillaud Dubois; E. Letamendia; E. Bouthry ; M.F. Lepetitcorps ; A. Benachi ; C. Vauloup Fellous
25 CONGENITAL CYTOMEGALOVIRUS INFECTION WITH MINOR LESIONS AT FETAL MRI: A 12 YEARS EXPERIENCE TO IMPROVE COUNSELLING SKILLS C. Doneda; B. Scelsam; P. Introvini; M. Zavattoni; S. Orcesi; G. Lombardi; L. Pugni; M. Fumagalli; M. Rustico; E. Fabbri; V. Tien Tu; G. Izzo; M. Genovese; C. Parazzini; B. Tassis; A. Ronchi; C. Pietrasanta; F. Triulzi
13
26 CMV INFECTION: RELATIVES BETWEEN MOTHER’S AMNION FLUID AND THEIR CHILDREN’S UMBILICAL BLOOD C. Perillaud Dubois; E. Letamendia; E. Bouthry; M.F. Lepetitcorps; A. Benachi; C. Vauloup Fellous 27 FETAL CMV INFECTION, DILEMMA FOR DIAGNOSIS AND PROGNOSIS N. Vedmedovska; A. Miskova; A. Krumiča; S. Dzelzite; L. Smane
28 PROSPECTIVE STUDY ON SENSORINEURAL HEARING LOSS (SNHL) IN A COHORT OF INFANTS WITH CONGENITAL CYTOMEGALOVIRUS (cCMV) INFECTION C. Marsico; M. G. Capretti; C. S. Nigro; L. Gabrielli; C. Brandolini; A. Benatti; G. Faldella; T. Lazzarotto
29 SEVERE CONGENITAL CYTOMEGALOVIRUS INFECTION J. Figueirinha; C. Ferreira; D. Bordalo; S. Rolim; M. Figueiredo; A. Pereira; S. Tomé
30 SECOND TRIMESTER SONOGRAPHIC SIGNS OF FETAL CMV LESIONS WITHOUT MATERNAL CONFIRMATION OF CMV INFECTION F. Monacci; F. Strigini; M. Pistello; R. Canapicchi; V. Nardini; T. Simoncini
31 THE NATURAL HISTORY OF HEARING DISORDERS IN ASYMPTOMATIC CONGENITAL CYTOMEGALOVIRUS INFECTION S. Salomè; A. Giannattasio; R. Malesci; E. Marciano; P. Dolce; G. Portella; P. Di Costanzo; E. Capone; C. Coppola; L. Capasso; F. Raimondi
32 CONGENITAL CYTOMEGALOVIRUS INFECTION AWARENESS AMONG PRENATAL HEALTH CARE PROVIDERS FOR WOMEN GIVING BIRTH AT A TERTIARY REFERRAL HOSPITAL IN BARCELONA (SPAIN) M. Valdés-Bango 1; K. Castillo; A. Hawkins ; L. Guirado ; E. Scazzocchio; F. Figueras; A. Goncé
33 CMV INFECTION IN PEDIATRIC RESIDENTS: EPIDEMIOLOGY AND AWARENESS P. Rodríguez Molino; T. del Rosal; C. Calvo; M. Muñoz San José; D. Blázquez Gamero; Maria José Mellado; M. de la Calle; M. Cabanes Borrallo; F. Baquero-Artigao
34 INVESTIGATION OF CYTOMEGALOVIRUS-SPECIFIC IGM: COMPARISON BETWEEN THREE COMMERCIAL KITS AND IMMUNOBLOTTING T. Lazzarotto; A. Chiereghin; G.Turello; E.C. Borgatti; G. Piccirilli; I. Cataneo; L. Gabrielli; G. Simonazzi
14
35 HIGH CMV REPLICATION IN THE FOETAL HIPPOCAMPUS G. Piccirilli; L. Gabrielli; A. Chiereghin; M.P. Bonasoni; G. Turello; E. C. Borgatti; G. Simonazzi; N. Salfi; C. Ceccarelli; D. Santini; T. Lazzarotto
36 CONGENITAL CMV AFTER SECONDARY MATERNAL INFECTION. PRENATAL POSTNATAL CORRELATION CASE REPORT A.M. Martinez Sapiña; J. Pascual Mancho; V. Paris Boj; R. M. Fernandez Esgueva; Pinillos Pison; P. Abenia; P. Seral; M.C.Tajada Duaso
37 PRENATAL ULTRASOUND FEATURES IN CONGENITAL CYTOMEGALOVIRUS M. Lanna; E. Fabbri; A Quarenghi; S. Faiola; A Garofalo; C. Doneda; I. Cetin; M.A. Rustico
38 TREATMENT OF PRETERM INFANTS WITH CONGENITAL CMV INFECTION F. Lorenzoni; M. Del Pistoia; S. D’Elios; M. Ferrara; M. Ciantelli; P. Ghirri
39 DOES VALGANCICLOVIR TREATMENT IMPROVE WHITE MATTER ABNORMALITIES IN CONGENITAL CYTOMEGALOVIRUS INFECTION? G. Forner; F. De Osti; E. Trincia; M. Bendini; I. Inches; E. Vian; N. Mainin
40 FETAL TREATMENT OF CMV INFECTION WITH VALACICLOVIR – A SINGLE CENTER EXPERIENCE – LISBON 2004-2018 M. Martins; A. Cohen
41 ROLE OF GLYCOPROTEIN (G)O AND GH GENOTYPES IN CONGENITAL CMV INFECTION: SEARCHING FOR VIRAL PROGNOSTIC MARKERS I. Taravillo; N. Moral; C. Pascual; A. Pérez-Rivilla; M.D. Folgueira
42 COUNSELING AND PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS: 20 YEARS’ EXPERIENCE OF AN ITALIAN REGIONAL REFERENCE CENTRE G. Esposito; A. Giudicepietro; S. Tagliaferri; L. L. Mazzarelli; L. Sarno; A. Sirico; F.Quaglia; G. Saccone; T. Guerritore; M. Di Cresce; F. Zullo; P. Martinelli; G.M. Maruotti
43 AMNIOCENTESIS FOR PRENATAL DIAGNOSIS OF CYTOMEGALOVIRUS INFECTION: WHAT COUNSELING AFTER A NEGATIVE PCR OF CMV-DNA? G. Esposito; S. Salomè; A. Giudicepietro; S. Tagliaferri; L. L. Mazzarelli; L. Sarno; A. Sirico; P. Di Costanzo; C. Coppola; G. Saccone; F. Zullo; P. Martinelli; F. Raimondi; G. M. Maruotti
15
44 DIAGNOSIS OF FETAL CMV INFECTION DURING PREGNANCY M. Fernández-Esgueva; J. Pascual-Mancho; R. Pinillos-Pison; P. Abenia-Uson; M. L. Roc-Alfaro; A. Martinez-Sapiña
45 CMV INFECTION RATE DURING PREGNANCY IN GREECE: ONE YEAR STUDY D. Bountouvas; D. Lampropoulou; E. Alchazidou; G. Petrakos
46 CYTOMEGALOVIRUS IN PREGNANCY: AN OBSERVATIONAL STUDY TO ASSESS OBSTETRIC PROVIDER KNOWLEDGE ABOUT PREVENTIVE PRACTICES AND DIAGNOSIS C. Boccherini; V. D’Ambrosio; F. Vena; S. Corno; C. Pajno; P. Ciolli; F. Rech; R. Brunelli; D. Di Mascio; P. Benedetti Panici; A. Giancotti
47 KNOWLEDGE OF CONGENITAL CYTOMEGALOVIRUS (CCMV) AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE UNIT IN A TERTIARY PERINATAL CENTER F. Vena; V. D’Ambrosio; C. Boccherini; C. Pajno; S. Corno; P. Ciolli; F. Rech; D. Di Mascio; R. Brunelli P. Benedetti Panici; A. Giancotti
48 SCREENING, DIAGNOSIS AND TREATMENT CCMV N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; H. Sarkisyan; Z. Morozova
49 SEVERE CCMV INFECTION, CASE REPORT N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; H. Sarkisyan; Z. Morozova
50 CMV ENTEROCOLITIS IN NEONATES, THREE CASE REPORTS N. Vaynshteyn; E. Britanishskaya; J. Mitina; T. Matveeva; A. Chubarova; N. Krivova
51 CONGENITAL CMV INFECTION – 8 YEAR EXPERIENCE OF A PORTUGUESE CENTER I. Ferreira; A. Amorim; E. Martins; M. Ferreira; R. Barroso
52 HYPERIMMUNOGLOBULIN THERAPY. PORTUGUESE PRENATAL DIAGNOSIS CENTER´S EXPERIENCE J. R. Silva; M.M Carrilho; F. Valente
53 THE EFFICACY OF ANTIVIRAL TREATMENT IN INFANTS WITH CONGENITAL CYTOMEGALOVIRUS INFECTION WITH OR WITHOUT HEARING LOSS D. Ari-Even Roth; M. Tepperberg-Oikawa; Y. Henkin; G. Barkai
16
WITH SPECIAL THANKS TO
17
COMPANY PROFILES
ROCHE
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world. Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.
18
ELITECH
ELITechGroup manufactures and distributes diagnostic products for clinical chemistry, microbiology, hematology and molecular biology though direct sales and a distribution network encompassing more than 100 countries.ELITechGroup is a leading PCR innovator with the revolutionary Minor Groove Binder technology and has become today a global solution provider for Molecular Diagnostics. Our culture of innovation, combined with the highest manufacturing quality standard and long-lasting collaborations with customers and international working groups enables us to design and manufacture superior sensitivity and specificity real-time PCR assays for infectious disease testing, immunocompromised patient monitoring, antibiotic resistance control, oncohematology, and genetic testing.
MSD
MSD Italia is the Italian affiliate of Merck & Co., Inc., NJ, USA, which is in over 140 countries with 70,000 employees, providing innovative healthcare solutions and increasing access to therapies through targeted policies, programs and partnerships. In Italy the Company operates since 1956 with productive, commercial and research activities providing medicines, vaccines, biological therapies and animal health products
BIOMÉRIEUX
BioMérieux is a world leader in the field of in vitro diagnostics and has a longstanding commitment to the fight against infectious diseases. We provide diagnostic solutions that include bacteriology & virology reagents, instruments, IT solutions and services along with the leading BioFire Syndromic testing products. Each of our products is designed to allow clinicians to take more rapid and informed clinical decisions with actionable results to fight antimicrobial resistance and reduce inappropriate antibiotic use for better patient care.bioMérieux is present worldwide in more than 150 countries through 43 subsidiaries and distributors.
19
GENERAL INFORMATION
CONGRESS VENUE
Istituto degli Innocenti Piazza della Santissima Annunziata, 12, 50122 Firenze FI
CONGRESS MATERIAL
Participants can collect badge and congress material at the Registration desk located at the Salone delle Compagnie.Please note that admission to Scientific Session and exhibition area is restricted to participants wearing their badge
ORGANIZING SECETARIAT
MCA Events Srl Via Ambrogio Binda, 34 20143 Milano - Italy Ph. +39 02 34934404 | Fax +39 02 34934397 [email protected] www.mcascientificevents.eu
OPENING HOURS
Thursday, February 21st From 08.00 am to 5.30 pm Friday, February 22nd From 08.30 am to 4.40 pm
OFFICIAL LANGUAGE
English is the official language of the Congress.
20
CERTIFICATE OF ATTENDANCE
The Certificate of Attendance will be available to download on www.cmvcongress.eu at the end of the Congress.
INTERNATIONAL ACCREDITATION (UEMS)
UEMS – European Union of Medical Specialists: 10 credits recognized. The “CONGENITAL CMV – FROM PREGNANCY TO INFANCY: LET’S FACE IT” has been accredited by the European Accreditation Council for Continuing Medical Educational (EACCME) for the entire congress. EACCME credits are recognized Europe-wide and in North America they can be exchanged for their national equivalent by contacting your national CME authority.
ITALIAN ACCREDITATION (ECM – EDUCAZIONE CONTINUA IN MEDICINA)
N. EVENTO: 246907CREDITI ASSEGNATI: 7 CREDITI
Il Congresso è stato accreditato per le seguenti categorie:
· MEDICO CHIRURGO Discipline: Neonatologia, Pediatria, Pediatria (Pediatri di libera scelta), Ginecologia e Ostetricia
· INFERMIERE · INFERMIERE PEDIATRICO· OSTETRICA/O
L’erogazione dei crediti ECM da parte del provider è subordinata a:
1. alla partecipazione effettiva del 90% rispetto alla durata complessiva dell’evento formativo 2. alla compilazione del questionario di gradimento online3. alla corrispondenza tra la professione svolta e le discipline dichiarate, dal provider, al momento della richiesta di accreditamento 4. alla correttezza e completezza dei dati forniti su richiesta nella scheda anagrafica compilata.
21
NOTE
22
NOTE
23
NOTE
mcascientificevents.eu
cmvcongress.eu